Pharmaron Beijing (03759) contributes US$10 million to participate in an overseas equity investment fund.

Pharmaron Beijing (03759) announced that, in order to fully leverage the investment and research capabilities of professional investment institutions in the biopharmaceutical industry, Pharmaron UK Limited ("Pharmaron UK"), a wholly-owned subsidiary of the Company, intends to participate as a limited partner in the investment of HJ Double Helix Fund L.P. by subscribing for capital contributions of US$10 million with its own funds or self-raised funds. On November 6, 2026, Pharmaron UK signed the fund subscription documents, pursuant to which it subscribed for limited partnership interests in the Fund, subject to the relevant terms of the Fund's "Amended and Restated Agreement of Exempted Limited Partnership of HJ Double Helix Fund L.P." and entitled to the corresponding rights. The partnership primarily makes equity and equity-related investments in the global biotechnology sector, with a focus on nucleic acid drugs, cell and gene therapies, and investment opportunities in their upstream and/or downstream industries.